Evolus, Inc.
EOLS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001570562
In the last 90 days, Evolus, Inc. insiders filed 0 open-market purchases and 1 sale; 158 institutions reported holding it in 13F filings for Q2 2026, worth $335.1M in total; no superinvestor holds it.
Superinvestors holding EOLS, Q2 2026
No superinvestor reported holding EOLS in Q2 2026.
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of EOLS each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q2 2025
0 superinvestors holding at quarter end
- Sold out
- Soros Fund Management
Q1 2025
1 superinvestor holding at quarter end
- Reduced
- Soros Fund Management (−9.5%)
Q4 2024
1 superinvestor holding at quarter end
- Added
- Soros Fund Management (+29.4%)
Q2 2024
1 superinvestor holding at quarter end
- Added
- Soros Fund Management (+1.2%)
Q1 2024
1 superinvestor holding at quarter end
- Added
- Soros Fund Management (+52.7%)
Q4 2023
1 superinvestor holding at quarter end